Back in December, we wrote about a district court ruling rejecting the Federal Trade Comission’s (“FTC”) motion to enjoin the proposed combination of Thomas Jefferson University (“TJU”) and Albert Einstein Healthcare Network...more
The FTC, and antitrust enforcement in general, are having their moment. For example, in early January the Supreme Court heard oral arguments in AMG Capital Management v. Federal Trade Commission, a case questioning the FTC’s...more
2/10/2021
/ Administrative Law Judge (ALJ) ,
Administrative Proceedings ,
AMG Capital Management LLC v FTC ,
Article III ,
Department of Justice (DOJ) ,
Due Process ,
En Banc Review ,
Federal Trade Commission (FTC) ,
FTC Act ,
FTCA Section 13(b) ,
Jurisdiction ,
Legislative Agendas ,
Mergers ,
Restitution ,
SCOTUS ,
Seila Law LLC v Consumer Financial Protection Bureau ,
Separation of Powers ,
Standing
The Federal Trade Commission’s (“FTC”) recent winning streak in its ongoing challenges of hospital and physician mergers has, at least for now, ended in a Philadelphia U.S. district court. After six days of evidentiary...more
On September 29, 2020, Judge Sarah Pitlyk, a 2019 Trump appointee to the Eastern District of Missouri, granted the Federal Trade Commission’s request for a preliminary injunction barring two thermal coal producers, Arch...more
On Wednesday, an FTC Commissioner used the occasion of a routine report to Congress to send a warning shot to private equity firms, especially those rolling up health care providers. Commissioner Rohit Chopra, an advisor to...more
On October 22, 2018, the FTC announced it had reached a settlement with industrial gas suppliers Praxair, Inc. and Linde AG (the “Parties”) arising out of their proposed merger. According to the FTC’s Complaint, issued by 4-1...more
11/1/2018
/ Acquisitions ,
Competition ,
Divestiture ,
Divestment ,
Energy Sector ,
Federal Trade Commission (FTC) ,
Mergers ,
Oil & Gas ,
Private Equity Firms ,
Public Comment ,
The Clayton Act
On Wednesday, November 8, 2017 the Federal Trade Commission (FTC) hosted a workshop seeking to explore the general question of why the cost of prescription drugs has risen greatly in recent history. The Workshop was framed...more
11/17/2017
/ Competition ,
Drug Pricing ,
Federal Trade Commission (FTC) ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
GPOs ,
Hatch-Waxman ,
Intermediaries ,
Manufacturers ,
Pharmaceutical Industry ,
Prescription Drugs ,
Public Comment ,
Supply Chain